Table 2.
Association of antiretroviral resistance mutations in the PR regiona according to HIV-1 subtypes in naïve and ARV failing children and adolescents.
| Drug-naïve |
ARV failing |
||||||
|---|---|---|---|---|---|---|---|
| PR mutationsa |
n (%) of mutations |
PR mutations |
n (%) of mutations |
||||
| B subtypeb n = 22 |
Non-B subtype n = 13 |
pc | B subtype n = 48 |
Non-B subtype n = 18 |
p | ||
| L10F/I/V | 2 (9.1) | 5 (38.5) | 0,03 | L10F/I/V | 7 (14.6) | 10 (55.5) | <0.01 |
| K20I/R/M/T | 0 | 5 (38.5) | <0.01 | K20I/R/M/T | 6 (12.5) | 13 (72.2) | <0.01 |
| L24I | 0 | 0 | – | L24I | 2 (4.2) | 2 (11.1) | NS |
| L33F/V | 0 | 0 | – | L33F/V | 4 (8.3) | 2 (11.1) | NS |
| M36I/V | 3 (13.6) | 12 (92.3) | <0.01 | M36I/V | 14 (29.2) | 18 (100.0) | <0.01 |
| M46I/L | 0 | 0 | – | M46I/L | 3 (6.3) | 3 (16.6) | NS |
| I47A | 0 | 0 | – | I47A | 0 | 2 (11.1) | NS |
| I50L | 0 | 0 | – | I50L | 0 | 1 (5.5) | NS |
| I54V | 0 | 0 | – | I54V | 7 (14.6) | 4 (22.2) | NS |
| Q58E | 0 | 0 | – | Q58E | 2 (4.2) | 3 (16.6) | NS |
| I62V | 4 (18.2) | 2 (15.4) | NS* | I62V | 12 (25.0) | 5 (27.7) | NS |
| I63P | 4 (18.2) | 0 | NS | I63P | 30 (62.5) | 5 (27.7) | 0.01 |
| I64L/V | 4 (18.2) | 0 | NS | I64L/V | 14 (29.2) | 0 | 0.01 |
| A71V/T | 3 (13.6) | 0 | NS | A71V/T | 6 (12.5) | 3 (16.6) | NS |
| L76V | 0 | 0 | – | L76V | 0 | 1 (5.5) | NS |
| V77I | 5 (22.7) | 2 (15.4) | NS | V77I | 10 (20.8) | 2 (11.1) | NS |
| V82A | 0 | 0 | – | V82A | 8 (16.6) | 4 (22.2) | NS |
| N83D | 0 | 0 | – | N83D | 1 (2.1) | 0 | NS |
| N88D | 0 | 0 | – | N88D | 4 (8.3) | 0 | NS |
| L90M | 0 | 0 | – | L90M | 2 (4.2) | 2 (11.1) | NS |
| I93L | 5 (22.7) | 2 (15.4) | NS | I93L | 5 (10.4) | 7 (38.8) | <0.01 |
a
Protease region.
b
n, number of subjects carrying the subtype for the indicated gene region.
c
p-Value; qui-square test.
*
NS, no statistical significance.